Research Papers:
The 3′UTR signature defines a highly metastatic subgroup of triple-negative breast cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1875 views | HTML 2731 views | ?
Abstract
Lei Wang1,2,3, Xin Hu1,2,3, Peng Wang4,5, Zhi-Ming Shao1,2,3,6
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
2Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
4Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China
5School of Life Science and Technology, ShanghaiTech University, Shanghai, China
6Institutes of Biomedical Sciences, Fudan University, Shanghai, China
Corresponding to:
Zhi-Ming Shao, email: [email protected]
Peng Wang, email: [email protected]
Xin Hu, email: [email protected]
Keywords: prognostic modeling, 3′ untranslated region, alternative polyadenylation, triple-negative breast cancer, biomarker
Received: February 6, 2016 Accepted: July 18, 2016 Published: August 01, 2016
ABSTRACT
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3′UTR patterns to improve postoperative risk stratification. We collected 327 publicly available microarrays and generated the 3′UTR landscape based on expression ratios of alternative 3′UTR. After initial feature filtering, we built a 17-3′UTR-based classifier using an elastic net model. Time-dependent ROC comparisons and Kaplan–Meier analyses confirmed an outstanding discriminating power of our prognostic model for TNBC patients. In the training cohort, 5-year event-free survival (EFS) was 78.6% (95% CI 71.2–86.0) for the low-risk group, and 16.3% (95% CI 2.3–30.4) for the high-risk group (log-rank p<0.0001; hazard ratio [HR] 8.29, 95% CI 4.78–14.4), In the validation set, 5-year EFS was 75.6% (95% CI 68.0–83.2) for the low-risk group, and 33.2% (95% CI 17.1–49.3) for the high-risk group (log-rank p<0.0001; HR 3.17, 95% CI 1.66–5.42). In conclusion, the 17-3′UTR-based classifier provides a superior prognostic performance for estimating disease recurrence and metastasis in TNBC patients and it may permit personalized management strategies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10975